Literature DB >> 23748606

Incidentally discovered pancreatic intraepithelial neoplasia: what is its clinical significance?

Ioannis T Konstantinidis1, Eduardo F Vinuela, Laura H Tang, David S Klimstra, Michael I D'Angelica, Ronald P Dematteo, T Peter Kingham, Yuman Fong, William R Jarnagin, Peter J Allen.   

Abstract

PURPOSE: Pancreatic intraepithelial neoplasia (PanIN) is a presumed precursor of pancreatic ductal adenocarcinoma (PDAC). We assessed the relationship between incidental PanIN after resection of non-adenocarcinoma lesions and the development of metachronous PDAC in the remnant.
METHODS: We retrospectively reviewed the clinicopathologic data of patients who underwent pancreatectomy for non-PDAC from January 2000 to January 2010. Intraductal papillary mucinous lesions were excluded. All available postoperative imaging and clinical follow-up data were reviewed; the risk of developing PDAC was assessed in patients with a minimum follow-up time of 6 months and with imaging studies available for review.
RESULTS: A total of 584 patients were analyzed. Median age was 59 years (range 10-85 years), and 338 (58 %) were female. The most common lesions for which resection was performed were serous cystic neoplasms (17 %), pancreatic neuroendocrine tumors (38 %), metastatic tumors (9 %), and mucinous cystic neoplasms (7 %). PanIN was identified in 153 (26 %) patients. The majority of these patients had PanIN-1 or -2 (50 and 41 %, respectively), whereas 13 (8 %) had PanIN-3. Of the 506 (87 %) patients with adequate follow-up (median 3.7 years, range 0.5-12.6 years), 1 patient (0.2 %) with PanIN identified at the time of initial resection developed cancer in the remnant. This occurred 4.4 years after a distal pancreatectomy in the setting of PanIN-1B. No patient with PanIN-3 developed cancer during follow-up.
CONCLUSIONS: PanIN was identified in 26 % of patients who underwent resection for histopathology other than PDAC. The presence of PanIN of any grade did not result in an appreciable cancer risk in the pancreatic remnant after short-term follow-up.

Entities:  

Mesh:

Year:  2013        PMID: 23748606     DOI: 10.1245/s10434-013-3042-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas.

Authors:  Olca Basturk; Seung-Mo Hong; Laura D Wood; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Lodewijk A A Brosens; Noriyoshi Fukushima; Michael Goggins; Ralph H Hruban; Yo Kato; David S Klimstra; Günter Klöppel; Alyssa Krasinskas; Daniel S Longnecker; Hanno Matthaei; G Johan A Offerhaus; Michio Shimizu; Kyoichi Takaori; Benoit Terris; Shinichi Yachida; Irene Esposito; Toru Furukawa
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

Review 2.  Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.

Authors:  Meredith L Stone; Gregory L Beatty
Journal:  Pharmacol Ther       Date:  2019-05-31       Impact factor: 12.310

Review 3.  Pancreatic Cancer: A Review.

Authors:  Wungki Park; Akhil Chawla; Eileen M O'Reilly
Journal:  JAMA       Date:  2021-09-07       Impact factor: 157.335

Review 4.  Pancreatic adenocarcinoma pathology: changing "landscape".

Authors:  Lodewijk A A Brosens; Wenzel M Hackeng; G Johan Offerhaus; Ralph H Hruban; Laura D Wood
Journal:  J Gastrointest Oncol       Date:  2015-08

Review 5.  [Ductal adenocarcinoma and unusual differential diagnosis].

Authors:  P Haage; C A Schwartz; C Scharwächter
Journal:  Radiologe       Date:  2016-04       Impact factor: 0.635

6.  Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm.

Authors:  Krushna C Patra; Nabeel Bardeesy; Yusuke Mizukami
Journal:  Clin Transl Gastroenterol       Date:  2017-04-06       Impact factor: 4.488

7.  Clinical significance of pancreatic intraepithelial neoplasia in resectable pancreatic cancer on survivals.

Authors:  Da-Young Yu; Young-Dong Yu; Wan-Bae Kim; Hyung-Joon Han; Sae-Byul Choi; Dong-Sik Kim; Sang-Yong Choi; Joo-Young Kim; Hyeyoon Chang; Baek-Hui Kim
Journal:  Ann Surg Treat Res       Date:  2018-04-30       Impact factor: 1.859

8.  Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma.

Authors:  Tsengelmaa Jamiyan; Takayuki Shiraki; Yoshihiro Kurata; Masanori Ichinose; Keiichi Kubota; Yasuo Imai
Journal:  World J Surg Oncol       Date:  2020-06-22       Impact factor: 2.754

9.  Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model.

Authors:  Mary Linton B Peters; Andrew Eckel; Peter P Mueller; Angela C Tramontano; Davis T Weaver; Anna Lietz; Chin Hur; Chung Yin Kong; Pari V Pandharipande
Journal:  Pancreatology       Date:  2018-07-29       Impact factor: 3.977

10.  MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model.

Authors:  Eva M Serrao; Mikko I Kettunen; Tiago B Rodrigues; Piotr Dzien; Alan J Wright; Aarthi Gopinathan; Ferdia A Gallagher; David Y Lewis; Kristopher K Frese; Jaime Almeida; William J Howat; David A Tuveson; Kevin M Brindle
Journal:  Gut       Date:  2015-09-07       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.